SEC Form 4 · accession 0001209191-18-011403
CELGENE CORP /DE/ · CELG
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gilla Kaplan
Director
Period of report
Feb 15, 2018
Accepted (ET)
Feb 20, 2018 · 5:02 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000816284
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 15, 2018 | M | 9,250 | $27.18 | A | 94,801 | D | |
| Common StockF1 | Feb 15, 2018 | S | 9,250 | $95.989 | D | 85,551 | D | |
| Common Stock | Feb 20, 2018 | S | 9,250 | $94.83 | D | 76,301 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F3,F2 | $27.18 | Feb 15, 2018 | M | 9,250 | D | — | Mar 17, 2018 | Common Stock | 9,250 | 0 | D |
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were sold by the reporting person in multiple transactions at prices ranging from $95.987 to $96.00, inclusive. The reporting person undertakes to provide to Celgene Corporation (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.
- F2The option was fully exercisable.
- F3The option was issued pursuant to the Company's 1995 Non-Employee Director's Incentive Plan.